Other
Insulin Sensitivity
0
Pipeline Programs↗
4
Active Trials↗
8
Companies Involved↗
Insulin Sensitivity is an early-stage landscape with 0 programs across 8 companies. The most active players are AstraZeneca, Mario Negri Institute for Pharmacological Research, Ionis Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
62
clinical trials
Completed47 · 76%
Terminated5 · 8%
Unknown status5 · 8%
Recruiting3 · 5%
Withdrawn1 · 2%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
62 trials
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Recruiting·—·Phase 4·NCT07271771·40 enrolled
Aerobic Versus Resistance Exercises on Insulin Sensitivity in Obese Patients
Active, not recruiting·—·Phase 1·NCT06772857·3 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)